January 2005
Worldwide Biotech;Jan2005, Vol. 17 Issue 1, p4
Trade Publication
Reports on the commercial supply agreement signed by Lorus Therapeutics Inc. with Diagnostic Chemicals Limited, operating as BioVectra dcl for the commercial manufacture of Virulizin. Information on BioVectra; Number of patients enrolled for the clinical trial of Virulizin; Background of Lorus.


Related Articles

  • Lorus and BioVectra sign pancreatic cancer drug deal.  // PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p14 

    Reports on the commercial supply agreement between Lorus Therapeutics Inc. and BioVectra DCL company for pancreatic cancer candidate Virulizin. Completion of the technology transfer process to BioVectra; Evaluation on the use of Virulizin as a treatment of advanced pancreatic cancer in...

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase II trial of Lorus Therapeutics Inc.'s LOR-2040 plus cytarabine regimen which showed a 28 percent complete remission rate in acute myeloid leukemia.

  • In the pipeline.  // Contemporary Urology;Aug2002, Vol. 14 Issue 8, p68 

    Presents news briefs related to medicine as of August 2002. Efforts of Lorus Therapeutics to conduct clinical trial on GTI-2040 for use in combination with capecitabine for the treatment of renal cell carcinoma; Results from a clinical study designed to evaluate the efficacy of tadalafil;...

  • LORUS THERAPEUTICS REPORTS 2ND QTR '06 NET LOSS OF $5.1 MIL.  // Biotech Financial Reports;Mar2006, p1 

    This article presents information on the financial performance of Lorus Therapeutics Inc. in the 2nd quarter of 2006. Lorus Therapeutics has reported second quarter results for fiscal year 2006 for the three and six-month periods ending on November 30, 2005. It is informed that the company...

  • CLINIC ROUNDUP.  // BioWorld Today;9/10/2008, Vol. 19 Issue 176, p4 

    This section offers clinical news briefs as of September 10, 2008. Lorus Therapeutics Inc. of Toronto, Canada issued published data on observations gathered during the clinical trial of LOR-2040. Phase II clinical test of MN-221, an anti-asthmatic drug of San Diego, California-based MediciNova...

  • Clinic Roundup.  // BioWorld Today;6/15/2012, Vol. 23 Issue 116, p6 

    This section offers news briefs related to clinical trials. Biomay AG revealed that its vaccine for grass pollen allergy improved the condition of patients in a Phase IIa trial. Positive findings were found by CytoPharm Inc. and Amarillo Biosciences Inc. in their Phase II trial of oral...

  • INDUSTRY UPDATE - Other Cancers.  // PharmaWatch: Cancer;April 2003, Vol. 2 Issue 4, p14 

    Reports developments related to cancer as of March 2003. Positive opinion received by Novartis AG from European regulators at the Committee for Proprietary Medicinal Products over a label update for its Zometa drug; Patent granted to protect the R1 component of ribonucleotide reductase of Lorus...

  • Prostate Cancer News Headlines May 15, 2003--June 14, 2003.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Presents an update on developments concerning prostate cancer treatment, compiled as of June 14, 2003. Lorus' plan to advance its anticancer drug, GTI-2501 into phase II clinical trial; Association of the drug, Zometa, with increased bone mineral density in prostate cancer treatment;...

  • Lorus to advance its anticancer drug, GTI-2501 into phase II clinical trial.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Announces the plan of Lorus Therapeutics to advance its antisense, anticancer drug, GTI-2501 into a phase II clinical trial for the treatment of advanced metastatic prostate cancer, in the fall of 2003. Mechanism of action of GTI-2501 observed during preclinical investigations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics